EpigralNSE:EPIGRAL -1.67%83 Gross Margin % is 42.27% as of Mar. 2026, which is 12% below its 10-year median of 48.29. GuruFocus rates NSE:EPIGRAL with a GF Score™ of 83/100 and a GF Value™ of ₹1,764.02 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 1,555 Chemicals companies, Epigral ranks better than 85.85% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Epigral's Gross Profit for the
three
months ended in Mar. 2026 was ₹3,111 Mil. Epigral's Revenue for the
three
months ended in Mar. 2026 was ₹7,362 Mil. Therefore, Epigral's Gross Margin % for the quarter that ended in Mar. 2026 was 42.27%.
Warning Sign:
Epigral Ltd gross margin has been in long-term decline. The average rate of decline per year is -4.2%.
The historical rank and industry rank for Epigral's Gross Margin % or its related term are showing as below:
NSE:EPIGRAL'
s Gross Margin % Range Over the Past 10 Years
Min: 40.02 Med: 48.29 Max: 62.12
Current: 43.43
During the past 9 years, the highestGross Margin % of Epigral was 62.12%. The lowest was 40.02%. And the median was 48.29%.
NSE:EPIGRAL's Gross Margin % is ranked better than 85.85% of 1555
companies
in the Chemicals industry
Industry Median: 23.44
vs NSE:EPIGRAL: 43.43
Epigral had a gross margin of 42.27% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Epigral was -4.20% per year.
Epigral (NSE:EPIGRAL) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Epigral had a gross margin of 42.27% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Epigral Gross Margin % Related Terms
Epigral Gross Margin % Historical Data
* Premium members only.
The historical data trend for Epigral's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Chemicals subindustry, Epigral's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Epigral Gross Margin % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Epigral's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Epigral's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Epigral (NSE:EPIGRAL) has a Gross Margin % of 42.27% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Epigral and its competitors. This is 12% below median its historical median of 48.29. Over the past decade, Epigral's Gross Margin % has ranged from 40.02 to 62.12. According to the industry distribution chart, Epigral ranks #220 out of 1555 companies in the Chemicals industry, placing it in the top 14.1%.
Is Epigral's Gross Margin % too high?
Epigral's current Gross Margin % of 42.27% is 12% below median its 10-year median of 48.29. Over the past 10 years, this metric has ranged from a low of 40.02 to a high of 62.12. The Chemicals industry median Gross Margin % is 23.44. Epigral's value of 42.27% is 80.3% above this industry median. Based on the distribution chart, Epigral ranks #220 out of 1555 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers. Overall, Epigral has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Epigral's Gross Margin % compare to DOW?
According to the Chemicals industry distribution chart, Epigral ranks #220 out of 1555 companies for Gross Margin %. This places Epigral in the top 14% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 23.44. Epigral's value of 42.27% is 80.3% above this benchmark. Historically, Epigral's own Gross Margin % has ranged from 40.02 to 62.12 over the past decade. While the company's 10-year median is 48.29 vs. the industry median of 23.44, Epigral has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Chemicals company?
The median Gross Margin % among Chemicals companies is 23.44, based on 1,555 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Epigral's current Gross Margin % of 42.27% is 80.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Epigral and its competitors. For the Chemicals industry, the median Gross Margin % is 23.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Epigral's current Gross Margin % is 42.27%, which is 12% below median its own 10-year median of 48.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Epigral stock overvalued right now?
Based on GuruFocus' analysis, Epigral (NSE:EPIGRAL) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹1,764.02, compared to a current price of ₹1,021.60 — trading 42.1% below its estimated fair value. The current Gross Margin % is 42.27%, which is 12% below median its 10-year median of 48.29 and 80.3% above the Chemicals industry median of 23.44. Epigral's overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Epigral (NSE:EPIGRAL), the current Gross Margin % is 42.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Epigral (NSE:EPIGRAL) Overvalued in 2026?
Based on GuruFocus' analysis, Epigral stock appears to be undervalued.
The current stock price of ₹1,021.60 is trading 42.1% below its estimated GF Value™ of ₹1,764.02.
GuruFocus considers Epigral to be Significantly Undervalued.
Key valuation signals for NSE:EPIGRAL:
Gross Margin %: 42.27% (12% below median its 10-year median of 48.29)
GF Value™: ₹1,764.02 vs. price of ₹1,021.60 (42.1% below fair value)
Industry Position: 80.3% above the Chemicals median (#220 of 1555)
No single metric tells the full story. See the NSE:EPIGRAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Epigral Ltd is a producer of Chlor-Alkali and its Derivatives and specialty chemicals with backward and forward integration facilities. It manufactures Caustic Soda, Caustic Potash, CPVC Resin, Epichlorohydrin, Chlorine, Hydrogen, Chloromethanes, and Hydrogen Peroxide. The company is focused on servicing domestic as well as international markets.
83GF Score
Get the complete analysis for NSE:EPIGRAL
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:EPIGRAL has been successfully added to your 
